Author | Peter Young

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

A review of market performance and trends in 2018 and first quarter of 2019 for the life sciences industry.

What the new rules mean for Chinese-related investments and acquisitions in the US.

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.